SG11202004115WA - Edasalonexent dosing regimen for treating muscular dystrophy - Google Patents
Edasalonexent dosing regimen for treating muscular dystrophyInfo
- Publication number
- SG11202004115WA SG11202004115WA SG11202004115WA SG11202004115WA SG11202004115WA SG 11202004115W A SG11202004115W A SG 11202004115WA SG 11202004115W A SG11202004115W A SG 11202004115WA SG 11202004115W A SG11202004115W A SG 11202004115WA SG 11202004115W A SG11202004115W A SG 11202004115WA
- Authority
- SG
- Singapore
- Prior art keywords
- edasalonexent
- muscular dystrophy
- dosing regimen
- treating muscular
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762581981P | 2017-11-06 | 2017-11-06 | |
PCT/US2018/059283 WO2019090271A1 (en) | 2017-11-06 | 2018-11-05 | Edasalonexent dosing regimen for treating muscular dystrophy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202004115WA true SG11202004115WA (en) | 2020-06-29 |
Family
ID=66332350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202004115WA SG11202004115WA (en) | 2017-11-06 | 2018-11-05 | Edasalonexent dosing regimen for treating muscular dystrophy |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210023029A1 (en) |
EP (1) | EP3706730A4 (en) |
JP (1) | JP2021502328A (en) |
KR (1) | KR20200084877A (en) |
CN (1) | CN111315372A (en) |
AU (1) | AU2018359969A1 (en) |
BR (1) | BR112020009020A2 (en) |
CA (1) | CA3078727A1 (en) |
CL (1) | CL2020001180A1 (en) |
CO (1) | CO2020006395A2 (en) |
IL (1) | IL274375A (en) |
MX (1) | MX2020004659A (en) |
PH (1) | PH12020550526A1 (en) |
RU (1) | RU2020118258A (en) |
SG (1) | SG11202004115WA (en) |
WO (1) | WO2019090271A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020191087A1 (en) * | 2019-03-18 | 2020-09-24 | Ptc Therapeutics, Inc. | Therapeutic combinations for use in treating a muscular dystrophy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2315740T1 (en) * | 2008-07-08 | 2018-03-30 | Catabasis Pharmaceuticals, Inc. | Fatty acid acetylated salicylates and their uses |
PT2519230T (en) * | 2009-12-31 | 2019-01-18 | Marius Pharmaceuticals Llc | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
NZ601698A (en) * | 2010-01-08 | 2015-04-24 | Catabasis Pharmaceuticals Inc | Fatty acid fumarate derivatives and their uses |
-
2018
- 2018-11-05 CN CN201880071203.6A patent/CN111315372A/en active Pending
- 2018-11-05 RU RU2020118258A patent/RU2020118258A/en unknown
- 2018-11-05 EP EP18874489.0A patent/EP3706730A4/en not_active Withdrawn
- 2018-11-05 BR BR112020009020-4A patent/BR112020009020A2/en not_active Application Discontinuation
- 2018-11-05 KR KR1020207015893A patent/KR20200084877A/en unknown
- 2018-11-05 CA CA3078727A patent/CA3078727A1/en not_active Abandoned
- 2018-11-05 US US16/761,783 patent/US20210023029A1/en not_active Abandoned
- 2018-11-05 SG SG11202004115WA patent/SG11202004115WA/en unknown
- 2018-11-05 WO PCT/US2018/059283 patent/WO2019090271A1/en active Application Filing
- 2018-11-05 JP JP2020520142A patent/JP2021502328A/en active Pending
- 2018-11-05 MX MX2020004659A patent/MX2020004659A/en unknown
- 2018-11-05 AU AU2018359969A patent/AU2018359969A1/en not_active Abandoned
-
2020
- 2020-04-30 PH PH12020550526A patent/PH12020550526A1/en unknown
- 2020-04-30 IL IL274375A patent/IL274375A/en unknown
- 2020-05-05 CL CL2020001180A patent/CL2020001180A1/en unknown
- 2020-05-27 CO CONC2020/0006395A patent/CO2020006395A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20200084877A (en) | 2020-07-13 |
BR112020009020A2 (en) | 2020-10-27 |
RU2020118258A (en) | 2021-12-08 |
EP3706730A4 (en) | 2021-08-11 |
WO2019090271A1 (en) | 2019-05-09 |
IL274375A (en) | 2020-06-30 |
CA3078727A1 (en) | 2019-05-09 |
CL2020001180A1 (en) | 2020-09-25 |
CO2020006395A2 (en) | 2020-06-09 |
JP2021502328A (en) | 2021-01-28 |
CN111315372A (en) | 2020-06-19 |
EP3706730A1 (en) | 2020-09-16 |
US20210023029A1 (en) | 2021-01-28 |
AU2018359969A1 (en) | 2020-05-14 |
PH12020550526A1 (en) | 2021-05-10 |
MX2020004659A (en) | 2020-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1258823A1 (en) | Methods for treating muscular dystrophy | |
GB201713653D0 (en) | Dosage regimen | |
SI3347054T1 (en) | Dosing regimens for anti-tf-antibody drug-conjugates | |
EP3389589C0 (en) | Dosing device | |
HK1259491A1 (en) | Dosing regimens | |
IL272791A (en) | Methods for treating muscular dystrophy | |
HRP20181572T1 (en) | Fgf-18 compound dosing regimen | |
IL273419A (en) | Dosing regimen of siponimod | |
IL265762A (en) | Dosing regimen of avelumab for the treatment of cancer | |
GB2540877B (en) | A dosing apparatus | |
IL273382A (en) | Dosing regimen of siponimod | |
IL274375A (en) | Edasalonexent dosing regimen for treating muscular dystrophy | |
HK1249912A1 (en) | Anti-flt-1 antibodies for treating duchenne muscular dystrophy | |
IL266255A (en) | Novel dosage regimen | |
GB201720519D0 (en) | Dosing regimen | |
GB201718106D0 (en) | Dosing regimen | |
GB201718000D0 (en) | Dosing regimen | |
GB201717694D0 (en) | Dosing regimen | |
GB201609758D0 (en) | Dosing Regimen | |
GB201617850D0 (en) | Dosage regimen | |
GB201521216D0 (en) | Dosage regimen | |
GB201610502D0 (en) | Dosage regimen | |
GB201611236D0 (en) | Dosing tubes |